-$0.05 EPS Expected for Regulus Therapeutics Inc. (NASDAQ:RGLS) This Quarter

Equities research analysts predict that Regulus Therapeutics Inc. (NASDAQ:RGLS – Get Rating) will announce ($0.05) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Zero analysts have issued estimates for Regulus Therapeutics’ earnings. Regulus Therapeutics reported earnings of ($0.08) per share in the same quarter last year, which suggests a positive year over year growth rate of 37.5%. The business is expected to report its next earnings results on Monday, January 1st.

On average, analysts expect that Regulus Therapeutics will report full-year earnings of ($0.22) per share for the current year, with EPS estimates ranging from ($0.25) to ($0.19). Zacks Investment Research’s EPS calculations are an average based on a survey of research analysts that follow Regulus Therapeutics.

Regulus Therapeutics (NASDAQ:RGLS – Get Rating) last issued its quarterly earnings results on Thursday, March 10th. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.05) by ($0.02). During the same period last year, the business posted ($0.03) EPS.

A number of equities analysts recently commented on RGLS shares. StockNews.com initiated coverage on shares of Regulus Therapeutics in a research report on Monday, April 11th. They set a “sell” rating on the stock. Zacks Investment Research cut shares of Regulus Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, March 16th. Finally, HC Wainwright restated a “buy” rating and set a $2.00 price objective on shares of Regulus Therapeutics in a research report on Tuesday, January 25th.

Hedge funds have recently added to or reduced their stakes in the company. Commonwealth Equity Services LLC raised its position in shares of Regulus Therapeutics by 38.8% during the third quarter. Commonwealth Equity Services LLC now owns 111,000 shares of the biopharmaceutical company’s stock worth $76,000 after acquiring an additional 31,000 shares during the last quarter. Morgan Stanley raised its holdings in Regulus Therapeutics by 2,799.7% during the 1st quarter. Morgan Stanley now owns 163,251 shares of the biopharmaceutical company’s stock worth $255,000 after purchasing an additional 157,621 shares during the last quarter. Geode Capital Management LLC boosted its position in Regulus Therapeutics by 13.8% during the third quarter. Geode Capital Management LLC now owns 670,747 shares of the biopharmaceutical company’s stock valued at $463,000 after acquiring an additional 81,551 shares during the last quarter. Asymmetry Capital Management L.P. boosted its position in shares of Regulus Therapeutics by 94.9% during the 4th quarter. Asymmetry Capital Management L.P. now owns 2,731,044 shares of the biopharmaceutical company’s stock valued at $860,000 after purchasing an additional 1,329,553 shares in the last quarter. Finally, DAFNA Capital Management LLC acquired a new stake in Regulus Therapeutics during the fourth quarter worth approximately $1,750,000. 51.47% of the stock is owned by hedge funds and other institutional investors.

Shares of NASDAQ RGLS traded down $0.02 during midday trading on Monday, reaching $0.23. The company’s stock had a trading volume of 22,025 shares, compared to its average volume of 1,323,579. Regulus Therapeutics has a fifty-two week low of $0.19 and a fifty-two week high of $1.55. The stock has a market capitalization of $33.57 million, a price-to-earnings ratio of -0.70 and a beta of 2.16. The company has a current ratio of 12.48, a quick ratio of 12.48 and a debt-to-equity ratio of 0.09. The stock has a 50 day simple moving average of $0.27 and a 200-day simple moving average of $0.35.

About Regulus Therapeutics (Get Rating)

Regulus Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease.

Featured Stories